Text Size

Gut Hormones After Oral Versus Intravenous Amino Acids

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bo Ahren, Lund University
ClinicalTrials.gov Identifier:
NCT01366768
First received: May 31, 2011
Last updated: October 9, 2012
Last verified: October 2012
History of Changes
  Purpose

The study hypothesis is that gut hormones are released after oral but not intravenous amino acids which result in stimulation of insulin secretion.


Condition Intervention
Normal Non-fluency
 Other: Oral amino acid mixture
Other: Intravenous amino acid administration

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Release of Gut Hormones After Oral Versus Intravenous Amino Acids

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Lund University:

Primary Outcome Measures:
  • Gut hormone secretion [ Time Frame: 300 min ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Insulin secretion [ Time Frame: 300 min ] [ Designated as safety issue: No ]

Enrollment: 12
Study Start Date: May 2011
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oral amino acid mixture
Oral administration of amino acid mixture in healthy volunteers
 Other: Oral amino acid mixture
Amino acid mixture 2,93 ml/kg
Other Name: Amino acid mixture
Experimental: Intravenous amino acid administration
Intravenous infusion of amino acid mixture in healthy volunteers
 Other: Intravenous amino acid administration
Amino acid mixture 2,93 ml/kg
Other Name: Amino acid mixture

Detailed Description:

Amino acid mixture is given orally or intravenously to match total concentrations of amino acids in healthy subjects. Samples are taken regularly for 300 min after administrations. Plasma levels of the gut hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)and determined and related to plasma levels of insulin and glucagon.

  Eligibility

Ages Eligible for Study:   20 Years to 30 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy subjects

Exclusion Criteria:

  • Diabetes
  • Liver disease
  • Kidney disease
  • Thyroid disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01366768

Locations
Sweden
Department of Clinical Sciences Lund, Lund University
Lund, Sweden, 221 84
Sponsors and Collaborators
Lund University
Investigators
Principal Investigator: Bo Ahrén, PhD Lund University
  More Information

No publications provided

Responsible Party: Bo Ahren, Professor, Lund University
ClinicalTrials.gov Identifier: NCT01366768     History of Changes
Other Study ID Numbers: 003
Study First Received: May 31, 2011
Last Updated: October 9, 2012
Health Authority: Sweden: Medical Products Agency

Keywords provided by Lund University:
Gut hormones
Insulin secretion
Normal physiology

Additional relevant MeSH terms:
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 22, 2013